Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Nurix Therapeutics, Inc. from 31 Aug 2019 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Nurix Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Aug 2019 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Nov 2025 was $78,221,000, a 34% decline year-over-year.
  • Nurix Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 30 Nov 2025 was $263,697,000, a 36% decline year-over-year.
  • Nurix Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $263,697,000, a 36% decline from 2024.
  • Nurix Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $193,299,000, a 34% decline from 2023.
  • Nurix Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $143,948,000, a 20% increase from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Nurix Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $263,697,000 $78,221,000 -$19,680,000 -34% 01 Sep 2025 30 Nov 2025 10-K 28 Jan 2026 2025 FY
Q3 2025 $244,017,000 $86,421,000 -$37,547,000 -77% 01 Jun 2025 31 Aug 2025 10-Q 09 Oct 2025 2025 Q3
Q2 2025 $206,470,000 $42,704,000 +$1,752,000 +3.9% 01 Mar 2025 31 May 2025 10-Q 09 Jul 2025 2025 Q2
Q1 2025 $208,222,000 $56,351,000 -$14,923,000 -36% 01 Dec 2024 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q4 2024 $193,299,000 $58,541,000 -$16,585,000 -40% 01 Sep 2024 30 Nov 2024 10-K 28 Jan 2026 2025 FY
Q3 2024 $176,714,000 $48,874,000 -$11,892,000 -32% 01 Jun 2024 31 Aug 2024 10-Q 09 Oct 2025 2025 Q3
Q2 2024 $164,822,000 $44,456,000 -$20,179,000 -83% 01 Mar 2024 31 May 2024 10-Q 09 Jul 2025 2025 Q2
Q1 2024 $144,643,000 $41,428,000 -$695,000 -1.7% 01 Dec 2023 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q4 2023 $143,948,000 $41,956,000 +$4,761,000 +10% 01 Sep 2023 30 Nov 2023 10-K 28 Jan 2026 2025 FY
Q3 2023 $148,709,000 $36,982,000 +$8,727,000 +19% 01 Jun 2023 31 Aug 2023 10-Q 11 Oct 2024 2024 Q3
Q2 2023 $157,436,000 $24,277,000 +$21,124,000 +47% 01 Mar 2023 31 May 2023 10-Q 11 Jul 2024 2024 Q2
Q1 2023 $178,560,000 $40,733,000 +$1,800,000 +4.2% 01 Dec 2022 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q4 2022 $180,360,000 $46,717,000 -$9,059,000 -24% 01 Sep 2022 30 Nov 2022 10-K 28 Jan 2025 2024 FY
Q3 2022 $171,301,000 $45,709,000 -$16,751,000 -58% 01 Jun 2022 31 Aug 2022 10-Q 06 Oct 2022 2022 Q3
Q2 2022 $154,550,000 $45,401,000 -$19,158,000 -73% 01 Mar 2022 31 May 2022 10-Q 07 Jul 2022 2022 Q2
Q1 2022 $135,392,000 $42,533,000 -$18,329,000 -76% 01 Dec 2021 28 Feb 2022 10-Q 08 Apr 2022 2022 Q1
Q4 2021 $117,063,000 $37,658,000 -$17,785,000 -89% 01 Sep 2021 30 Nov 2021 10-K 09 Feb 2023 2022 FY
Q3 2021 $99,278,000 $28,958,000 -$10,441,000 -56% 01 Jun 2021 31 Aug 2021 10-Q 06 Oct 2022 2022 Q3
Q2 2021 $88,837,000 $26,243,000 -$13,236,000 -102% 01 Mar 2021 31 May 2021 10-Q 07 Jul 2022 2022 Q2
Q1 2021 $75,601,000 $24,204,000 -$11,824,000 -96% 01 Dec 2020 28 Feb 2021 10-Q 08 Apr 2022 2022 Q1
Q4 2020 $63,777,000 $19,873,000 01 Sep 2020 30 Nov 2020 10-K 28 Jan 2022 2021 FY
Q3 2020 $18,517,000 -$16,100,000 -666% 01 Jun 2020 31 Aug 2020 10-Q 14 Oct 2021 2021 Q3
Q2 2020 $13,007,000 01 Mar 2020 31 May 2020 10-Q 13 Jul 2021 2021 Q2
Q1 2020 $12,380,000 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q1
Q3 2019 $2,417,000 01 Jun 2019 31 Aug 2019 10-Q 14 Oct 2020 2020 Q3

Nurix Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $263,697,000 -$70,398,000 -36% 01 Dec 2024 30 Nov 2025 10-K 28 Jan 2026 2025 FY
2024 $193,299,000 -$49,351,000 -34% 01 Dec 2023 30 Nov 2024 10-K 28 Jan 2026 2025 FY
2023 $143,948,000 +$36,412,000 +20% 01 Dec 2022 30 Nov 2023 10-K 28 Jan 2026 2025 FY
2022 $180,360,000 -$63,297,000 -54% 01 Dec 2021 30 Nov 2022 10-K 28 Jan 2025 2024 FY
2021 $117,063,000 -$53,286,000 -84% 01 Dec 2020 30 Nov 2021 10-K 09 Feb 2023 2022 FY
2020 $63,777,000 -$42,317,000 -197% 01 Dec 2019 30 Nov 2020 10-K 28 Jan 2022 2021 FY
2019 $21,460,000 01 Dec 2018 30 Nov 2019 10-K 28 Jan 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.